Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet
Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet
from home https://ift.tt/3oeQ6LW
from home https://ift.tt/3oeQ6LW
Bharat Biotech's Covaxin Safe, Phase 3 Trial Data Shows 77.8% Efficacy Against Symptomatic Covid: Lancet
![]()
Reviewed by Ranjit Updates
on
November 12, 2021
Rating:
No comments:
Please don't tag any Spam link in comment box